Is metronidazole safe for use during pregnancy?

Metronidazole Safety During Pregnancy

Metronidazole can be used safely during the second and third trimesters of pregnancy, but should be avoided in the first trimester except when clearly needed and alternative treatments are inadequate.

FDA Classification and Contraindications

• The FDA classifies metronidazole as Pregnancy Category B, indicating that animal reproduction studies have shown no evidence of impaired fertility or harm to the fetus, though adequate well-controlled studies in pregnant women are lacking 1.

• Metronidazole is contraindicated during the first trimester of pregnancy for trichomoniasis treatment 1.

• The drug crosses the placental barrier and enters fetal circulation rapidly, and its effects on human fetal organogenesis during the first trimester are not fully known 1.

Guideline Recommendations by Trimester

First Trimester

• Avoid metronidazole during the first trimester whenever possible 2.
• For bacterial vaginosis (BV) in the first trimester, clindamycin vaginal cream is the preferred alternative 2.
• For trichomoniasis in the first trimester, use should be carefully evaluated and restricted to cases where alternative treatment has been inadequate 1.

Second and Third Trimesters

• Metronidazole can be used after the first trimester for appropriate indications 2.

• For BV in high-risk pregnant women (those with previous preterm delivery), the CDC recommends metronidazole 250 mg orally three times daily for 7 days starting in the earliest part of the second trimester 2.

• For low-risk pregnant women with symptomatic BV, the same regimen is recommended to relieve symptoms 2.

• For trichomoniasis after the first trimester, metronidazole 2 g orally in a single dose is the recommended treatment 2.

• Lower doses are specifically recommended for pregnant women to minimize fetal exposure 2.

Evidence on Pregnancy Outcomes

Preterm Birth

• Current evidence does not confirm metronidazole's efficacy in reducing preterm birth risk when used alone 3.
• A meta-analysis found no overall benefit (pooled RR 1.10,95% CI 0.78-1.55), though subgroup analysis suggested potential harm with short-duration treatment (≤3 days) in high-risk women (RR 1.67,95% CI 1.07-2.62) 3.
• Multiple studies found no association between metronidazole treatment and preterm birth 4, 5.

Birth Defects and Congenital Anomalies

• No increased risk of major congenital malformations has been consistently demonstrated 4, 6.
• A large cohort study found no association between first-trimester metronidazole exposure and congenital anomalies (OR 0.86,95% CI 0.30-2.45) 4.
• Pooled analysis showed OR 1.15 (95% CI 0.98-1.34) for major malformations, which was not statistically significant 3.
• One specific concern identified was congenital hydrocephaly (OR 4.06,95% CI 1.75-9.42), though this requires further confirmation 3.

Spontaneous Abortion

• There is an increased risk of spontaneous abortion associated with metronidazole use (pooled OR 1.72,95% CI 1.40-2.12) 3.
• This represents approximately a 70% increased risk, though this must be interpreted cautiously as the underlying genitourinary infection itself may be the confounding factor 7.

Birth Weight

• Some studies have reported reduced neonatal birth weight in metronidazole-exposed pregnancies, even among term infants, though without increased prematurity rates 6.
• Other studies found no association with low birth weight 4.

Clinical Decision-Making Algorithm

For First Trimester:

1. Avoid metronidazole unless absolutely necessary
2. Use clindamycin vaginal cream for BV
3. For trichomoniasis, defer treatment if possible or use only when alternative treatments have failed

For Second and Third Trimesters:

1. Metronidazole can be used for appropriate indications
2. Use lower doses (250 mg three times daily rather than higher doses)
3. For BV in high-risk women, screen and treat in early second trimester
4. For symptomatic BV in low-risk women, treat to relieve symptoms

Important Caveats

• The increased spontaneous abortion risk should be discussed with patients, acknowledging that the underlying infection may be the actual causative factor rather than the medication 3, 7.

• While metronidazole shows carcinogenic activity in rodent studies with chronic administration, this has not translated to human teratogenicity in clinical studies 1.

• The U.S. Preventive Services Task Force recommends against screening for BV in low-risk asymptomatic pregnant women, as treatment lacks demonstrated benefit in this population 2.

• Data on metronidazole vaginal gel during pregnancy are limited, and systemic therapy is generally preferred to treat possible subclinical upper genital tract infections 2.